Result of AGM

Eco Animal Health Group PLC

08 September 2026

 

ECO Animal Health Group plc

("ECO" or the "Company")

Result of AGM

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that at its Annual General Meeting held today, all resolutions proposed to the meeting were duly passed.

Votes received in relation to each resolution were as follows:

Resolution	For	%	Discretionary	%	Against	%
01	40,995,074	99.99	Nil	0.00	2,613	0.01
02	39,661,956	96.75	Nil	0.00	1,334,091	3.25
03	33,768,644	82.37	Nil	0.00	7,227,403	17.63
04	40,788,883	99.49	Nil	0.00	210,973	0.51
05	40,776,422	99.46	Nil	0.00	223,434	0.54
06	34,911,562	85.15	Nil	0.00	6,088,294	14.85
07	40,792,175	99.49	Nil	0.00	207,681	0.51
08	40,977,864	99.94	Nil	0.00	21,992	0.06
09	39,661,524	96.74	Nil	0.00	1,338,033	3.26
10	34,697,718	84.63	Nil	0.00	6,301,162	15.37
11	39,598,611	96.58	Nil	0.00	1,400,269	3.42
12	40,955,848	99.89	Nil	0.00	43,709	0.11

-Ends-

 Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage	020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer	020 7496 3000
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden	020 3100 2000
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group's proprietary lead product, Aivlosin^® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN^® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group's website or LinkedIn page for further information.

 

END